Navigation Links
Longs Reports Preliminary February Retail Drug Store Sales
Date:3/6/2008

WALNUT CREEK, Calif., March 6 /PRNewswire-FirstCall/ -- Longs Drug Stores Corporation (NYSE: LDG) today reported preliminary total retail drug store sales of $379 million for the four-week period ended February 28, 2008, an increase of 3.2 percent from $368 million in the comparable period a year ago.

(Dollars in millions) 4 weeks ended February 28, 2008

Total retail drug store sales $379

Increase from comparable prior year

period 3.2%

Same-store sales increase:

Pharmacy 2.1%

Front-end 0.3%

Total 1.2%

About the Company

Headquartered in Walnut Creek, California, Longs Drug Stores Corporation (NYSE: LDG) is one of the most recognized retail drug store chains on the West Coast and in Hawaii. The Company operates 510 retail pharmacies and offers a wide assortment of merchandise focusing on health, wellness, beauty and convenience. Longs also provides pharmacy benefit management services and Medicare beneficiary prescription drug plans through its wholly-owned subsidiary, RxAmerica, LLC. Additional information about Longs and its services is available at http://www.longs.com and more information about RxAmerica is available at http://www.rxamerica.com.

Contact: Phyllis Proffer

925-979-3979


'/>"/>
SOURCE Longs Drug Stores Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Longs Drug Stores Corporation Reports Results for Fourth Quarter and Fiscal Year 2008
2. Longs Drug Stores Corporation Declares Cash Dividend on Common Shares
3. Treating oft ignored non-cancer health issues after cancer diagnosis prolongs survival
4. Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
5. Longs Drugs Plans to Become the First Retailer in Hawaii With Walk-in Medical Clinics
6. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
7. Longs Drugs Announces Immunization Program for the 2007/2008 Flu Season
8. CRH Medical reports preliminary year end results
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results
10. Carriage Services Reports 2007 Full Year Results
11. General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are held ... with process innovation in drug formulation and manufacturing. CoreRx offers its clients ... equipment in support of their development and manufacturing goals. , The company ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest ... chronic problems, I focus on preventative care with all my patients to alleviate possible future ... always feel free to contact my office and my trained staff will assist you in ...
(Date:4/25/2017)... ... April 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency ... Series, Outliers in Writing, set to publish in summer 2017. , Dr. Bobrow, ... University of Arizona College of Medicine. He also serves as Medical Director for the ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Company,s consumer product development program, based on its ... for Investigative Dermatology (SID) 76 th Annual ... promote the sciences relevant to skin health and ...
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
Breaking Medicine Technology: